We estimate that the CEO of Adient plc ($ADNT), Jerome J. Dorlack, received a compensation of $13,114,394 in 2025. This is an increase of 27.61% from an estimated $9,493,471 in 2024.
These estimates are based on a new DEF14A filing, filed with the SEC on January 21, 2026. Note that parsing errors may occur.
You can track $ADNT on Quiver Quantitative's $ADNT stock dashboard.
$ADNT Stock Insider Trading Activity
$ADNT Stock insiders have traded $ADNT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ADNT stock by insiders over the last 6 months:
- JEROME J. DORLACK (President and CEO) sold 12,000 shares for an estimated $273,240
- MICHEL PIERRE ROSE BERTHELIN (EVP, EMEA) sold 2,500 shares for an estimated $49,275
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ADNT Stock Hedge Fund Activity
We have seen 122 institutional investors add shares of $ADNT Stock stock to their portfolio, and 128 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 1,839,894 shares (-27.0%) from their portfolio in Q3 2025, for an estimated $44,304,647
- GOLDMAN SACHS GROUP INC added 1,140,714 shares (+102.6%) to their portfolio in Q3 2025, for an estimated $27,468,393
- QUANTEDGE CAPITAL PTE LTD added 1,036,111 shares (+4317.1%) to their portfolio in Q3 2025, for an estimated $24,949,552
- BLACKROCK, INC. removed 953,103 shares (-6.0%) from their portfolio in Q3 2025, for an estimated $22,950,720
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 718,538 shares (+61.3%) to their portfolio in Q3 2025, for an estimated $17,302,395
- HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC removed 684,880 shares (-21.1%) from their portfolio in Q3 2025, for an estimated $16,491,910
- ROYAL BANK OF CANADA added 607,950 shares (+502.8%) to their portfolio in Q3 2025, for an estimated $14,639,435
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ADNT Stock Analyst Ratings
Wall Street analysts have issued reports on $ADNT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 01/12/2026
- Stifel issued a "Buy" rating on 11/06/2025
- B of A Securities issued a "Underperform" rating on 09/10/2025
- Morgan Stanley issued a "Underweight" rating on 08/12/2025
To track analyst ratings and price targets for $ADNT Stock, check out Quiver Quantitative's $ADNT forecast page.
$ADNT Stock Price Targets
Multiple analysts have issued price targets for $ADNT recently. We have seen 8 analysts offer price targets for $ADNT in the last 6 months, with a median target of $24.0.
Here are some recent targets:
- Joseph Spak from UBS set a target price of $30.0 on 01/14/2026
- Colin Langan from Wells Fargo set a target price of $29.0 on 01/12/2026
- Adam Jonas from Morgan Stanley set a target price of $20.0 on 12/08/2025
- Michael Ward from Citigroup set a target price of $22.5 on 11/12/2025
- Dan Levy from Barclays set a target price of $24.0 on 11/07/2025
- Nathan Janes from Stifel set a target price of $24.0 on 11/06/2025
- Ryan Brinkman from JP Morgan set a target price of $24.0 on 11/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
